Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.

Corbus is advancing CRB-913, an oral peripherally restricted CB1 inverse agonist that showed rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study. The company expects to complete a 12-week Phase 1b dose-ranging study (n=240) in summer 2026.

News Market Reaction – CRBP

-6.02%

1 alert

-6.02% News Effect

On the day this news was published, CRBP declined 6.02%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 1a duration: 14 days Phase 1b duration: 12 weeks Phase 1b sample size: n=240 +2 more

5 metrics

Phase 1a duration 14 days CRB-913 Phase 1a SAD/MAD obesity study

Phase 1b duration 12 weeks Ongoing CRB-913 dose-ranging Phase 1b obesity study

Phase 1b sample size n=240 CRB-913 Phase 1b dose-ranging obesity trial

Summit date March 24, 2026 BMO 2026 Metabolic Health Summit panel participation

Panel time 12:45 pm Eastern Time CRBP participation in Emerging Companies Panel at BMO summit

Market Reality Check

Price: $8.60 Vol: Volume 168,146 is below t...

normal vol

$8.60 Last Close

Volume Volume 168,146 is below the 20-day average of 222,741, suggesting limited trading interest ahead of the conference. normal

Technical Shares at $9.63 are trading below the 200-day MA of $10 and sit 53.16% under the 52-week high of $20.56 but above the 52-week low of $4.64.

Peers on Argus

CRBP is up 1.26% while key biotech peers like BMEA, PYXS, EQ, FATE, and KALA are...

1 Up

CRBP is up 1.26% while key biotech peers like BMEA, PYXS, EQ, FATE, and KALA are all down between roughly 3–7%. Momentum scanner shows only one peer (IOBT) moving up and not on news, indicating today’s action in CRBP is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Earnings and pipeline	Positive	+19.2%	Q4 and 2025 results with CRB-701/CRB-913 data and cash runway update.
Feb 12	Conference appearance	Neutral	+2.8%	Announcement of CEO presentation and investor meetings at Oppenheimer conference.
Jan 05	Conference presentation	Neutral	-0.5%	J.P. Morgan Healthcare Conference corporate overview and one-on-one meetings.
Dec 11	Phase 1a results	Positive	-5.7%	CRB-913 Phase 1a results showing weight loss and favorable safety profile in obesity.
Dec 10	Data timing update	Neutral	-5.7%	Notice of upcoming CRB-913 Phase 1a data release and conference call schedule.

Pattern Detected

Stock reactions to Corbus news have been mixed: strong gains on the March 9 earnings/clinical update, but notable declines around CRB-913 Phase 1a data and its preview, indicating occasional sell-the-news behavior even on seemingly positive clinical announcements.

Recent Company History

Over the past six months, Corbus has highlighted steady clinical and corporate progress. On Dec 11, 2025, CRB-913 Phase 1a data showed 2.9% placebo‑adjusted weight loss with favorable safety, followed by initiation of the 240‑subject Phase 1b CANYON‑1 study. Multiple conference appearances in January and February 2026 kept investors updated. The Mar 9, 2026 Q4 and 2025 results paired strong CRB‑701 and CRB‑913 signals with a $75M offering and $163.3M cash. Today’s BMO summit panel fits this pattern of ongoing investor and KOL engagement around the obesity program.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2026-03-11

$300,000,000 registered capacity

An effective S-3 shelf filed on Mar 11, 2026 permits Corbus to offer up to $300,000,000 of various securities in one or more future transactions, providing flexibility to raise capital but also introducing potential equity or debt issuance over time.

Market Pulse Summary

The stock moved -6.0% in the session following this news. A negative reaction despite this routine c...

Analysis

The stock moved -6.0% in the session following this news. A negative reaction despite this routine conference announcement would fit a pattern where seemingly constructive clinical communications, such as the CRB‑913 Phase 1a results on Dec 11, 2025, coincided with selling pressure. The new $300,000,000 shelf filed on Mar 11, 2026 also expanded capital-raising flexibility, which can weigh on sentiment if investors anticipate equity issuance. Past volatility around data and financing events suggests downside moves have not always reflected fundamental setbacks.

Key Terms

cb1 inverse agonist, phase 1a, dose-ranging

3 terms

cb1 inverse agonist medical

"CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment"

A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.

phase 1a medical

"favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

dose-ranging medical

"complete an ongoing Phase 1b dose-ranging 12-week study (n=240) in summer 2026."

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. Not financial advice.

NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026.

Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long-term weight management solution for people struggling with chronic obesity. Corbus expects to complete an ongoing Phase 1b dose-ranging 12-week study (n=240) in summer 2026.

BMO 2026 Metabolic Health Summit
Emerging Companies Panel: What's Next in the Treatment of Metabolic Disease
Date: March 24, 2026
Time: 12:45 pm Eastern Time

The BMO 2026 Metabolic Health Summit will convene industry-leading BioPharma innovators, experts, and investors for a full day of thought leadership panels, fireside conversations with corporate management, and small-group or one-on-one meetings exploring the future of metabolic health innovation.

Participants interested in one-on-one meetings with Dr. Cohen at the summit should contact their BMO representative.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners.  Their use does not imply affiliation or endorsement by these companies.  

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

When will Corbus (CRBP) present at the BMO 2026 Metabolic Health Summit?

Corbus CEO Yuval Cohen will participate on March 24, 2026 at 12:45 pm ET. According to Corbus, the appearance is part of the Emerging Companies Panel on metabolic disease treatments.

What is CRB-913 and what did Corbus (CRBP) report about it?

CRB-913 is an oral, peripherally restricted CB1 inverse agonist for obesity treatment. According to Corbus, it produced potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study.

When does Corbus (CRBP) expect to complete the Phase 1b study for CRB-913?

Corbus expects to complete the ongoing 12-week Phase 1b dose-ranging study (n=240) in summer 2026. According to Corbus, this study will inform dosing for later trials.

How can investors arrange one-on-one meetings with Corbus (CRBP) at the summit?

Investors should contact their BMO representative to request one-on-one meetings with Dr. Cohen. According to Corbus, BMO will coordinate small-group and individual meeting schedules at the summit.

What topics will Corbus (CRBP) likely discuss at the BMO 2026 Metabolic Health Summit?

Corbus will discuss developments in metabolic disease treatment and CRB-913 clinical progress. According to Corbus, the panel focuses on what's next in treating metabolic disease and innovation trends.